Maze Therapeutics prices $150 million stock offering at $23.50 per share

Maze Therapeutics Inc. (NASDAQ: MAZE) priced an underwritten registered offering of 5.54 million shares of common stock at $23.50 per share. The company also offered pre-funded warrants to purchase up to 850,000 shares at $23.499 per warrant to certain investors.

The gross proceeds from the offering are expected to reach $150 million before deducting underwriting discounts and other expenses. The offering is scheduled to close on April 23, 2026, subject to customary closing conditions.

Participants in the offering include both new and existing investors such as Farallon Capital Management, accounts advised by T. Rowe Price Investment Management Inc., Frazier Life Sciences, Janus Henderson Investors, Deep Track Capital, and Driehaus Capital Management. Leerink Partners LLC serves as the sole underwriter.

Maze plans to use the net proceeds primarily to advance research and development of its product candidates, including MZE829 for APOL1-mediated kidney disease and MZE782 for phenylketonuria and chronic kidney disease. The company stated the proceeds, combined with current cash and securities, are expected to fund operations into 2029 based on its current business plan.

The South San Francisco-based biopharmaceutical company focuses on developing small molecule precision medicines for kidney and metabolic diseases. The offering is conducted under a shelf registration statement that became effective with the Securities and Exchange Commission on February 4, 2026.

You May Also Be Interested In

• SpaceX files for 555.56M share IPO at $135/sh
• Bitmine Immersion Technologies plans $300 million preferred stock offering
• CXAI acquires EngineRoom for $12 million revenue run-rate